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Abstract
Background: In 2012 England and Wales experienced a resurgence of pertussis and an increase in infant deaths.
This occurred 8 years after acellular pertussis (aP) vaccine replaced whole cell (wP) primary vaccine despite
continued high coverage for the primary series and pre-school aP booster. We developed a mathematical model to
describe pertussis transmission dynamics in England and Wales since the 1950s and used it to investigate the cause
of the resurgence and the potential impact of additional vaccination strategies.
Methods: An age-structured, compartmental, deterministic model of the pertussis transmission dynamics was fitted
to 60 continuous years of age-stratified pertussis notification data in England and Wales. The model incorporated
vaccine-induced and natural immunity and differentiated between vaccine-induced protection against clinical
disease and infection.
Results: The degree of protection of wP vaccine against infection was estimated to be higher than that of aP
vaccine. Furthermore, the duration of protection for natural and wP-induced immunity was likely to be at least
15 years, but for aP vaccine it could be as low as 5 years. Model results indicated that the likely cause of the
resurgence was the replacement of wP by less efficacious aP vaccine and that an elevated level of pertussis would
continue. The collapse in wP vaccine coverage in the 1970s and resultant outbreaks in the late 1970s and early
1980s could not explain the resurgence. Addition of an adolescent or toddler booster was predicted to have little
impact on the disease in infants.
Conclusions: Our findings support the recent recommendation by the World Health Organisation that countries
currently using wP vaccine for primary immunisation should not change to aP vaccine unless additional strategies
to control infant disease such as maternal immunisation can be assured. Improved pertussis vaccines that provide
better protection against infection are needed.
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Background
England and Wales, in common with several other
countries, recently experienced a resurgence of pertussis
despite sustained high vaccine coverage. A recent review
of pertussis epidemiology in countries with and without
a resurgence by the World Health Organisation (WHO)
Strategic Advisory Group of Experts (SAGE) found that,
while there was no evidence of a global resurgence in
disease, the countries with clear evidence of a resurgence
had all replaced whole cell pertussis (wP) with acellular
pertussis (aP) vaccines 6–9 years previously [1].
Prior to the introduction of wP vaccine in England
and Wales in 1957, around 100,000 cases of pertussis
were reported annually. The wP vaccination programme
successfully reduced pertussis incidence until vaccine
coverage collapsed in the 1970s and 1980s following
publications that suggested a possible link between wP
vaccine and brain damage (Fig. 1a and Additional file 1).
This fall in coverage led to large pertussis outbreaks in
the late 1970s and 1980s [2]. Vaccine coverage then
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increased steadily as public and professional confidence
in the vaccine was restored, reaching 92 % in 1992 and
remaining high thereafter (Fig. 1b). Despite sustained
high coverage from the early 1990s, pertussis among in-
fants younger than 3 months who were too young to be
vaccinated still caused around 270 hospitalisations per
100,000 up to year 2000 [3]. In 2001, a booster dose of a
three- or five-component aP-containing vaccine given to
children between 3 ½ and 5 years of age was introduced
in the United Kingdom (UK) to reduce transmission
among older children and consequently to infants [2, 4].
No other boosters are currently given in the UK. In
2004, the primary wP vaccine given at 2, 3 and 4 months
of age [2] was replaced with aP vaccine, prompted by
the decision to change from oral to inactivated polio
vaccine (IPV) for which the only available IPV combin-
ation vaccine was one containing an aP component [2,
5]. The aP vaccine used exclusively in the UK until June
2014 was a five-component product (Pediacel®, Sanofi
Pasteur MSD) containing pertussis toxin, filamentous
haemagglutinin, pertactin and fimbrial antigens 2 and 3.
The pertussis resurgence that occurred in England and
Wales in 2012 resulted in an increase in deaths and hos-
pitalisations among infants too young to have received
their first dose of vaccine under the primary schedule.
To provide immediate passive protection to vulnerable
infants, a maternal pertussis immunisation programme
with an aP-containing vaccine was introduced in 2012 as
a temporary outbreak control measure. The programme
successfully reduced pertussis morbidity and mortality
among infants in England [4], but its long-term continu-
ation will depend on whether the elevated levels of per-
tussis seen in the resurgence are likely to continue. We
developed mathematical models to describe the pertussis
transmission dynamics in England and Wales and to
explore the following: the likely cause of the resurgence,
in particular whether the change from wP to aP vaccine
or the decline in vaccine coverage in the 1970s and
1980s contributed to the resurgence; whether the higher
incidence of disease in infants can be expected to con-
tinue; and the impact of the addition of a toddler or ado-
lescent booster to the existing programme.
Methods
We developed an age-structured, compartmental deter-
ministic model to describe pertussis transmission dy-
namics and the impact of vaccination. We distinguish
between natural and vaccine-induced immunity and be-
tween protection against clinical disease and infection.
As suggested by the baboon challenge studies of Warfel
et al. [6, 7], we assumed that natural and vaccine-
induced immunity completely protect against clinically
typical (i.e. notifiable) pertussis symptoms, but that vac-
cination only offers partial protection against acquiring
and transmitting infection, the degree potentially varying
between wP and aP vaccines. We also assumed that both
natural and vaccine-induced immunity wane with time
and that, if re-infected, an individual has a lower prob-
ability of developing notifiable disease. The waning pa-
rameters for natural, wP and aP protection against
disease, the degree of protection from aP and wP vac-
cines against infection and the probability of being noti-
fied with a first compared with a second infection were
estimated by fitting the model to the age-specific notifi-
cation data for England and Wales shown in Fig. 1.
Model structure
The assumptions for unvaccinated individuals are as fol-
lows: all newborn infants are susceptible (S1); individuals
in S1 can become infected and enter the latent (non-
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Fig. 1 Number of annual notifications (a) between 1954 and 2013 and (b) between 1986 and 2013 in England and Wales in seven age groups,
and the historical vaccine coverage (course completed) for the primary and pre-school booster programmes (blue line: wP primary vaccine coverage,
red line: aP primary vaccine coverage, black line: aP pre-school booster vaccine coverage). Coverage data for 1957 to 1966 not collected but assumed
to be the same as in 1967 as it was added into an existing DT vaccine (available to download in Additional file 1)
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infectious) phase (L1) according to the age-group-
dependent force of infection (FOI, λ). The FOI for the
ith age group, λi, is calculated as follows:
λi tð Þ ¼
X
j¼1
9
Ij tð Þ  Cij  qj;
where Ij tð Þ is the sum of infectious individuals in the jth
age group at time t, Cij is the contact rate of the ith and
jth age groups and qj is the transmission probability per
contact in the jth age group.
After the latent period (1/σ), individuals become infec-
tious (I1) with a proportion (α1) of them developing no-
tifiable symptoms. At the end of the infectious period
(1/ γ), individuals gain natural immunity (R) against dis-
ease and infection; this immunity then wanes (waning
rate, ω) with individuals becoming secondary suscepti-
bles (S2). An individual in S2 can become infected again
according to the same FOI, λ, as an individual in S1, but
the proportion developing notifiable symptoms, α2, is
less than α1. The durations of the latent (L2) and infec-
tious periods (I2) in a secondary infection are the same
as for L1 and I1 and were assumed to be 7 and 15 days
respectively [8–10]. After clearing infection, individuals
in I2 gain natural immunity (R).
The assumptions for vaccinated individuals are as fol-
lows: on vaccination, individuals in S1 move to the cor-
responding acellular (aP) or whole cell (wP) protected
compartments depending on which vaccine they receive.
Vaccine-protected individuals can still be susceptible to
infection, though with a lesser FOI than individuals
in S1; therefore, these compartments are denoted as
wPS or aPS. This reduced FOI reflects some degree
of protection against infection (π) and can differ be-
tween aP and wP vaccines (πap and πwp respectively).
The FOI acting on individuals in the aPS and wPS
compartments is therefore λ(1− π). After clearing the
infection, vaccine-protected individuals acquire natural
immunity and enter the R compartment. The vaccine-
induced protection against notifiable symptoms and
the partial protection against infection wane in paral-
lel with each other, with the duration potentially dif-
fering between aP and wP vaccinated individuals (1/
aPω and 1/wPω respectively). Individuals in whom
vaccine-induced immunity has waned enter the S2
compartment. An aP booster, whether given in the
second year of life, at pre-school age or in adoles-
cence, has an effect on individuals in S1 and S2, and
moves them to aPS, where it was assumed that the
degree of protection against infection (π) and the
waning function (aPω) were the same as for a pri-
mary aP vaccinee and independent of whether aP or
wP vaccine was given for priming. The third dose in
the three-dose primary series is assumed to be given
at 4 months, at which age vaccinated infants enter
the wPS or aPS compartments.
The flowchart in Fig. 2 shows the transitions between
model compartments for vaccine-protected and unpro-
tected individuals.
Fig. 2 Flowchart of the pertussis transmission dynamic model with acellular and whole cell vaccine-protected groups. (The difference equations
describing the flows between compartments are given in Appendix 1 in Additional file 2)
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Data sources
Notifications of clinically suspected cases of pertussis are
the only data source that pre-dates the introduction of
wP vaccination and are still recorded. From 1950 on-
wards, notification data were available in the seven age
groups (or finer ones) used in the model and were pub-
lished in the Annual Reviews from the Registrar General
[11] and from 1972 to 1981 by the Office of Population
Censuses and Surveys [12] and thereafter as part of the
Notifications of Infectious Diseases (NOIDs) data set
[13]. The notification incidence in 1956 was assumed to
be the pre-vaccination equilibrium year, as it was close
to the average of the three-year pre-vaccination period
1954–1956.
Vaccine coverage data for the primary series were only
available from 1966, so the assumption was made that
the coverage between 1957 and 1965 was the same as
in 1966 (Fig. 1a), as the wP component was included in
the existing DT (diphtheria vaccine introduced in 1942
and tetanus component added in 1950) primary vac-
cine. Coverage for the pre-school booster introduced in
2001 was generally about 10 % lower than the primary
schedule [4, 14–16].
The mixing patterns between and within age groups
are critical determinants of the age-dependent FOIs. The
only available data on mixing patterns across all age
groups were collected via the POLYMOD contact survey
carried out in England in 2006 [17]. The POLYMOD
contact information for infants was sparse and so was
supplemented by data from a recent study in England
that documented the number and type of contacts expe-
rienced by infants younger than 1 year of age [18]. The
annual population changes and POLYMOD contact pat-
terns adjusted for changes in population structure be-
tween 1956 and 2030 are shown in Appendix 2 (Movies
A.1 and A.2) in Additional file 2.
Model fitting
As little is known about the transmission of pertussis, it
was decided to model pertussis with as few assumptions
as possible. Only the FOIs and α1 were fitted in order to
match the model output with the observed age-stratified
notification data from 1956. Other parameters, i.e. α2,
duration of natural immunity, the duration of wP- and
aP-induced immunity and the degree of wP and aP pro-
tection against infection were explored by running the
model with the given assumptions in Table 1. For this,
α2 was assumed to be lower than α1; hence scenarios
for α2 are expressed as a percentage of α1. Further-
more, it was assumed that the duration of protection
induced by wP could not be longer than the duration of
natural protection, and the duration of protection in-
duced by aP could not be longer than that of wP. The
minimum average duration of 5 years for aP protection
was based on epidemiological data from England that
showed no decline in aP vaccine effectiveness in the
period between completion of the primary series and
receipt of the pre-school booster [4]. Exploration of the
possible disease scenarios was divided hierarchically in
three steps: first the pre-vaccination era (1956), the wP
era (1957–2000) and subsequently the aP era (2001–
2013, including the aP booster introduced in 2001 and
the replacement of the wP primary vaccine with aP vac-
cine in 2004).
For the pre-vaccination period, the FOIs by age (nine
age groups) and α1 were fitted, using a static model,
given each of the combinations for the duration of nat-
ural infection (9 values from 10 to 50 years [19, 20]) and
α2/α1 (5 values, from 2–10 %). This resulted in 45 para-
meterised models which each reproduced the 1956 age-
stratified notification data. For clarity, the FOIs were
used to set the age-specific transmission probabilities
per contact (9 values) in combination with the POLY-
MOD contact matrix as adjusted to the 1956 population
(Appendix 2 in Additional file 2).
These 45 obtained scenarios were subsequently ap-
plied to the model in the wP era. Each of the 45 scenar-
ios was combined with the historical vaccine uptake and
with all possible combinations of degree (9 values) and
duration of protection of wP (11 values) with the restric-
tion that the duration of protection by wP could not be
longer than the duration of the natural immunity. The
best 5 % fitting scenarios (178 scenarios) among 3555
simulated scenarios were selected based on the Poisson
deviance of the model outputs to the historical notifica-
tion data (1956–2000).
Table 1 Model parameters varied in the fitting and simulation procedures to cover their uncertainty and the values varied for each
parameter
Parameter Values varied
Average duration of natural immunity (ω) 10, 15, 20, 25, 30, 35, 40, 45 and 50 years
Scale parameter for the proportion of second + infections that are notified
compared to proportion of first infections in unvaccinated individuals (α2/α1)
10 % (1/10), 5 % (1/20), 3.3 % (1/30), 2.5 % (1/40) and 2 % (1/50)
Degree of wP and aP vaccine protection against infection (πwp and πap) 10, 20, 30, 40, 50, 60, 70, 80 and 90 %
Average duration of wP and aP vaccine protection against infection and
disease (wPω and aPω)
5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5 and 30 years
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For the aP era the obtained 178 scenarios were com-
bined with the uptake of aP and possible combinations
of degree (9 values) and duration of protection (11
values). This time the duration of aP vaccine protection
could not be longer than that of wP [19–21]. Again, the
5 % best fitting (658) scenarios were selected among
13,158 simulated scenarios based on the Poisson devi-
ance of the model outputs to the historical notification
data (2001–2013). The obtained set of 658 scenarios was
used in projecting the future incidence.
Sensitivity analysis of the contact matrix
There are no separate sensitivity analyses of individual
model parameters apart from the mixing matrix, as
model outputs were generated with combinations of
possible parameter values within the potential ranges de-
fined in Table 1.
The POLYMOD mixing matrices were derived from
population surveys conducted in 2006 [17] and 2012
[18]; therefore, the data may not be appropriate to re-
flect the contact patterns up to 50 years earlier, even
after adjusting the mixing matrix with annual population
changes. Hence, we also ran the model using a classical
assortative mixing approach based on two extreme mix-
ing matrices, one that assumes mixing is exclusively
within the same age group (fully assortative) and one
that assumes equal mixing within and between age
groups (fully proportionate). The mixing parameter be-
tween the two extreme mixing matrices was estimated
by fitting to the post-vaccination data. By comparing the
model outputs using the classic assortative mixing ap-
proach, the robustness of the results generated with the
POLYMOD mixing approach was assessed (Appendix 3
in Additional file 2).
Results
Fitting
The proportion of first infections that are notified (α1)
from these selected scenarios was estimated to be be-
tween 13.6–14.7 %. Figure 3 presents the fitted mean,
maximum and minimum values of FOIs by age group at
the 1956 equilibrium year. The lower forces of infection
in 15+ age groups led to lower transmission probabilities
per contact, as shown in Appendix 2 in Additional file 2.
The parameter values for α2/α1, average duration of
natural and vaccine-induced protection (wP and aP) and
degree of protection (wP and aP) against infections for
the selected best fitting 658 scenarios (5 % of all simu-
lated scenarios) are shown in Fig. 4. The value of α2/α1
was estimated to be 5 % (1/20) or lower, implying that
secondary infections have much less chance of develop-
ing notifiable symptoms than first infections in an un-
vaccinated individual. Primary infections are therefore
the main driver of pertussis notification rates.
For wP vaccine, only scenarios with 80 % degree of
protection against infection were among the 5 % best fit-
ting scenarios, implying that wP vaccine has produced a
strong herd immunity during the wP post-vaccination
era. On the other hand, the aP vaccine scenarios selected
had a lower degree of protection against infection (and
thus a lesser herd protection) than wP, between 40–
90 %, with the values between the lower (second) and
upper (third) quartiles ranging from 50–80 %. For the
duration of wP protection against infection, scenarios
with a period between 20 and 27.5 years were selected
between the lower and upper quartiles, while the aP pro-
duced between 7.5 and 17.5 years for the same quartiles
(Fig. 4). Fitting results indicated a strong inverse correl-
ation between the duration and degree of aP vaccine
protection against infection (high degree paired to a low
duration and vice versa). For wP vaccine, such a correl-
ation could not be demonstrated, due to the single value
for the degree of protection against infection (80 %).
The model outputs by age group using the best fitting
scenarios and under the current vaccination programme
are shown in Fig. 5. Even though the fluctuations shown
in the data points were not precisely produced in the
model outputs, overall trends in number of notifications
were generally well reflected within age groups, particu-
larly during the resurgences in the 1970s and 1980s and
in 2012. Similar parameter estimation results from the
assortative mixing approach were obtained and are pre-
sented in Appendix 3 in Additional file 2.
Simulation results for alternative vaccination strategies
Using the best fit parameter estimates, we investigated
the impact of ten vaccination programme options as
Fig. 3 Mean, maximum and minimum values of the force of infection
by nine age groups derived from the 1956 pre-vaccination equilibrium
in England and Wales (among 45 combined scenarios with 9 different
durations of natural immunity and 5 different values of α2/α1)
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listed in Table 2 on the number of pertussis notifications
in infants less than 1 year of age for the period 1956 to
2030 (Fig. 6); the potential impact of continuing the ma-
ternal pertussis vaccination was not included in these
simulations.
These ten vaccination programme options were chosen
to investigate the potential causes of the resurgence, and
to explore the effect of alternative vaccination strategies.
Options 1 and 2 were simulated to investigate the impact
of replacing wP with aP in 2004. Options 3 and 4 were
simulated to investigate whether the collapse in vaccine
coverage in the 1970s and 1980s led to the resurgence by
assuming that coverage remained at 78 % between 1970
and 1986. Options 5 and 6 assessed respectively the im-
pact of an adolescent aP booster at 13 years old (5) and/or
a toddler aP booster at 12 months (Option 6A) or
18 months (Option 6B) of age added to the current strat-
egy in 2015. In particular, Option 7 was used to investigate
the impact of introducing both toddler (at 12 months) and
adolescent (at 13 years old) boosters in the same year
(2015). Option 8 investigated the impact of introducing a
vaccine with the same degree and duration of protection
against infection as wP in 2015. Options 9 and 10 investi-
gated the likely long-term impact if aP vaccine had been
introduced as the primary pertussis vaccine from 1957
with or without the vaccine coverage collapse in the 1970s
and 1980s.
If wP had been retained for primary vaccination, with
addition of the aP pre-school booster in 2001, the model
predicts that there would be no resurgence, irrespective
of the drop in vaccine coverage in the 1970s and 1980s
(Options 2 and 4 compared with Options 1 and 3).
Introduction of an adolescent and/or a toddler booster
at 12 months in 2015 was predicted to have little impact
on infant disease (Options 5, 6A and 7). Option 8, intro-
ducing a new vaccine with a higher degree or duration
of protection than aP vaccine, could in the longer term
lower the incidence of infant pertussis to the level before
the change to aP vaccine in 2004. If aP vaccine had been
used since 1956, the model predicts that, with or with-
out the drop in vaccine coverage in the 1970s and
1980s, there would not have been a resurgence in 2012,
though the incidence in infants would have equilibrated
at a level higher than observed throughout the period
(Options 9 and 10).
Simulation results from the assortative mixing ap-
proach were almost identical to those of the POLY-
MOD mixing approach as presented in Appendix 3 in
Additional file 2. The impact of the ten simulated
programme options in Table 2 using both POLYMOD
and assortative mixing approaches for the remaining
six age groups and the overall population can be seen
in the Graphical User Interface programme (available
to download in Additional file 3).
Fig. 4 Box plots of parameter estimates from the 2000 best fitting aP scenarios to historical notification data between 1956 and 2013 in England
and Wales. a Duration of natural immunity; b α2/α1; c duration of wP vaccine protection; d degree of whole cell vaccine protection against
infection; e duration of aP vaccine protection; f degree of acellular vaccine protection against infection. Red line for median, blue box for lower
and upper quartiles and black bars for minimum and maximum
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Fig. 5 Notification data (red line) between 1956 and 2013 in England and Wales and corresponding model outputs from best fitted scenarios
(blue box plots minimum, lower quartile, median, upper quartile and maximum) by seven age groups (a–g) and the overall population (h)
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Discussion
Our simulation results indicate that the likely cause of
the resurgence in pertussis in England and Wales in
2012 was the change in 2004 to an aP vaccine that pro-
vided a lesser degree and/or shorter duration of protec-
tion against infection than the previously used wP
vaccine. Although there was a collapse in vaccine cover-
age in the 1970s and 1980s, simulation results did not
suggest that this was a causal factor in the resurgence.
Our results also indicate that a continued higher inci-
dence of pertussis in infants and older age groups can be
expected in the future and suggest that the resurgence
that began in 2012 reflects the resetting of incidence at a
higher level when moving from the post-wP vaccine
equilibrium to the post-aP vaccine equilibrium.
Our results apply to the five-component aP vaccine,
which was used exclusively in the UK until 2014, but
other aP vaccines with fewer components are unlikely to
provide higher or more durable protection against infec-
tion. The wP vaccines used in the UK have varied over
the years, but all have shown consistently high protec-
tion in post-licensure studies after the potency criteria
were standardised in 1968 [2]. However, even with high
coverage using a good wP vaccine, and with an aP pre-
school booster, the average annual admission rate in
infants younger than 3 months in England and Wales
immediately before the change to aP vaccine was still
high at 156 per 100,000 and with an annual mortality
rate of 7.2 per million maternities [4]. This indicates the
need for improved pertussis vaccines that could more
effectively control pertussis transmission by inducing
durable sterilizing immunity.
There is considerable uncertainty about the epidemi-
ology of pertussis, posing problems for the building and
fitting of realistic mathematical models of pertussis trans-
mission dynamics. Atypical or mild infections can occur
in older age groups, probably associated with waning
immunity. There is however little data on their frequency
or role in transmission, though there are well-documented
instances of adults with a history of vaccination who de-
veloped a mild cough subsequently confirmed as pertussis
transmitting to infants [22], and parents with an undiag-
nosed cough illness have been shown to be the source of
infection in around half of infant cases [23, 24]. In our
model, we took account of this by assuming that those
who had been infected or vaccinated had less chance of
developing notifiable pertussis symptoms if re-infected
but could still transmit. Furthermore, we observed a low
force of infection in those aged 15+, suggesting a relatively
small contribution of these age groups to the wider trans-
mission. We also differentiated between protection against
infection and clinical disease. This was based on the ba-
boon challenge model [7], which showed that while both
aP and wP vaccines and natural immunity provided
complete protection against clinical pertussis, aP vacci-
nated baboons were colonised for up to 35 days and still
infectious though asymptomatic; wP vaccinated baboons
were infected for shorter periods than aP vaccinees,
whereas convalescent baboons developed sterilizing im-
munity on re-challenge [7]. In our simulations, the degree
of protection of wP against infection was estimated to be
at least 80 %, which accords with the estimate of 85 %
from a household contact study in Senegal for one of the
wP vaccines that has been used in the national
programme in the UK [25]. In contrast, the degree of pro-
tection for aP could be as low as 60 % (Fig. 4). For dur-
ation of protection, the best fitting wP scenarios were
mostly with durations of at least 15 years, similar to that
of natural immunity, and are consistent with estimates
from epidemiological studies [19]. Due to the relatively
short time aP vaccines have been used in England and
Wales, our model could not distinguish well between dif-
ferent values for the duration of aP protection, although,
unlike wP vaccine, durations as short as 5 years were
Table 2 List of ten different vaccination programme options for the long-term simulations between 1956 and 2030 in England and
Wales
Option Long-term vaccination programme
1 Continuation of the current strategy: wP primary from 1957 + aP pre-school booster in 2001 + change
to aP primary in 2004 but without the maternal immunisation programme that began in October 2012
2 wP primary used throughout with aP pre-school booster in 2001
3 Opt. 1 + without vaccine coverage drop in 1970s and 1980s
4 Opt. 2 + without vaccine coverage drop in 1970s and 1980s
5 Opt. 1 + aP booster at the age of 13 years in 2015
6 Opt. 1 + aP booster at 12 (6A) or 18 months (6B) in 2015
7 Opt. 1 + aP booster at 12 months and at 13 years in 2015
8 Opt. 1 + aP vaccine replacement with wP-like vaccine in 2015
9 aP primary vaccine from 1957 + aP pre-school booster in 2001
10 Opt. 9 without the vaccine coverage drop in 1970s and 1980s
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Fig. 6 Model outputs of the annual pertussis notification among infants less than a year old between 1956 and 2030 in England and Wales with
the ten different vaccination programme options as shown in Table 2 (excludes 6B, as it shows similar results to those of 6A) and blue box plots
showing minimum, lower quartile, median, upper quartile and maximum of the annual pertussis notifications from the best fitting scenarios)
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plausible (Fig. 4). The lower degree and/or shorter dur-
ation of aP vaccine protection against infection would re-
sult in reduced herd immunity compared with wP vaccine
and would increase transmission in the population, result-
ing in a resurgence. Epidemiological studies in Australia
and the USA — aP-using countries where pertussis resur-
gences have also occurred— suggest a shorter duration of
protection after priming with aP than wP vaccines [26, 27]
and rapid waning of protection after a pre-school or ado-
lescent booster dose [28–32].
Others have developed models to investigate the likely
cause of the recent resurgences of pertussis. Gambhir
et al. [21] developed a model fitted to 20 years of age-
stratified notified incidence data in the USA that allowed
for waning immunity and re-infection and different du-
rations of natural, wP- and aP-induced immunity. They
concluded that the US resurgence was most likely
caused by lower efficacy and duration of protection from
aP than wP vaccine. Campbell et al. [33] developed an
Australian model based on serological data and the
ability to reproduce broad epidemiological trends such
as the inter-epidemic period. The latter required an
intermediate stage of waned immunity, when boosting
without infectiousness occurs, before transition to a
low state, when boosting results in infectiousness. The
duration of this intermediate state was estimated to be
considerably longer after natural than vaccine-induced
immunity, though with little difference between aP and
wP vaccines. However, the model did not distinguish
much difference between aP and wP vaccines, and it
was concluded that the replacement of the aP toddler
with an adolescent booster dose in 2004 contributed to
the subsequent resurgence in 2008. Althouse and Scar-
pino [34] used models to analyse pertussis notification
and genetic data from the USA and England and Wales
and concluded that asymptomatic transmission in the
acellular vaccine era was the most parsimonious ex-
planation of the recent resurgences. However, their
compartment of asymptomatic infection is operation-
ally similar to our assumption that only a proportion of
infections is notified (i.e. the parameters α1 and α2)
and is not necessarily an alternative explanation to
waning protection in models that distinguish between
protection against notifiable disease and protection
against infection.
Use of notifications data for model fitting is ham-
pered by possible changes in surveillance sensitivity
over time, as reporting of clinical cases may become
more complete when new diagnostic methods are de-
veloped. Without independent information on the likely
magnitude of temporal changes in surveillance sensitiv-
ity within and between age groups, it is difficult to ac-
commodate this in the model fitting. For example, in
older age groups the introduction of serological testing
in 2001 in England and Wales is likely to have im-
proved reporting of cases in adults; however, this likely
increase in completeness of notifications was not taken
into account. Furthermore, we did not include maternal
immunisation, introduced in 2012, in our model. How-
ever, due to the timing of introduction, this would only
have had an effect on the disparity between observed
and predicted notifications in 2013.
Conclusions
Despite the inevitable limitations in developing and para-
meterising a realistic pertussis dynamic transmission model
based on a long historical data set, our simulations provide
valuable insights into the likely cause of the resurgence in
England and Wales and of the relative merits of different
control strategies. With the elevated incidence of infant
disease predicted to continue in the absence of a maternal
immunisation programme, there will be a continuing need
for this programme to protect vulnerable infants. Our
model predicts that introduction of an adolescent booster
would have little impact on infant disease, despite our
favourable and probably unrealistic assumption that it pro-
vides a similar duration of protection as achieved with the
three-dose primary infant course [25–29]. However, an
adolescent booster may be justified in terms of the direct
protection afforded to this age group who, while at very
low risk of hospital admission and death, can have a dis-
tressing and prolonged cough that interferes with their
sleep and daily activity [35]. Our model provides a quanti-
tative basis for conducting cost-effectiveness analyses of
adding pertussis vaccine to the combined tetanus/low-dose
diphtheria/inactivated polio booster vaccine currently of-
fered to this age group in England and Wales. Our findings
support the recent recommendation by the World Health
Organisation that countries currently using wP vaccine for
primary immunisation should continue to use wP vaccines,
and a switch from wP to aP should only be considered
when additional strategies to control infant disease such as
maternal immunisation can be assured [36].
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